Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Executive Summary

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Advertisement

Related Content

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal
EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus
Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy
Tasly Gains Products As Transgene Sells Up China JV Stake
Roivant Unveils An Autoimmune-Focused 'Vant' At Inaugural Pipeline Day
BioNTech Signs Rare Disease Co-Development Deal With Genevant & Licenses LNP Platform
Axovant Hopes Gene Silence Is Golden With Benitec Pact
Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline
GW's Epidiolex Approval Encouraging For Pharma-grade Cannabinoid Pipeline
Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel